PLK1 and neoplasm: This suggests a biologically relevant antitumor effect in a subset of patients (Ellis et al., 2015), underscoring the promise of PLK1 inhibition while simultaneously highlighting the challenge of tumor heterogeneity and the need for predictive biomarkers.